Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection

Journal of Viral Hepatitis

Volumn 16, Issue 2, 2009, Pages 91-93

  Chotiyaputta, W ^a   Lok, A S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG USE; EDITORIAL; HEPATITIS B; HUMAN; INFECTION RISK; PRIORITY JOURNAL; RISK FACTOR; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME;

EID: 59149099751     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2008.01067.x     Document Type: Editorial

References (11)

1. Mast EE, Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 1-31.
2. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and metaanalysis. BMJ 2006; 332: 328-336.
3. Zhang SL, Yue YF, Bai GQ, Shi L, Jiang H. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol 2004; 10: 437-438.
4. Tse K, Siu SLY, Yip KT et al. Immuno-prophylaxis of babies borne to hepatitis B carriers mothers. Hong Kong Med J 2006; 12: 368-374
5. del Canho R, Grosheide PM, Mazel JA et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997; 15: 1624-1630.
6. van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000; 32: 1040-1041.
7. van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003; 10: 294-297.
8. Li XM, Yang YB, Hou HY et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003; 9: 1501-1503.
9. Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection; a multicenter, randomized, double-blind, placebo-controlled study. J Viral Hepat 2008; JVH-00144-2008.R1.
10. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in USA. Available at: http://www.aidsinfo.nih.gov/contentfiles/perinatalGL.pdf (accessed 9 July 2008).
11. ter Borg MJ, Leemans WF, de Man RA, Janssen HL. Exacerbation of chronic hepatitis B infection after delivery. J Viral Hepat 2008; 15: 37-41.